NM23-H1B基因mRNA在卵巢上皮性肿瘤组织中表达的研究

Study on mRNA expression of the human novel gene NM23-H1B in ovarian tumor

目的研究NM23-H1B基因与卵巢上皮性肿瘤的相关性。方法收集2003年4月至2004年2月手术切除的卵巢上皮性肿瘤标本48份,其中卵巢上皮性癌(卵巢癌)40份,卵巢交界性上皮性肿瘤8份,正常卵巢组织标本8份。采用RT-PCR技术、RNA印迹(northern blot)法、原位杂交实验,检测NM23-H1B基因mRNA的表达。结果经RT-PCR方法检测在所有的标本中均有NM23-H1B基因mRNA的表达,在正常卵巢组织中表达较低,而在所有的卵巢肿瘤中表达均高于正常卵巢组织,早期(Ⅰ、Ⅱ期)卵巢癌中的表达高于晚期(Ⅲ、Ⅳ期)。northern blot法检测结果显示NM23-H1B基因mRNA在正常卵巢组织的表达较低,交界性肿瘤中的表达则与正常卵巢组织中相似,而在卵巢癌组织中表达明显增高,在早期卵巢癌中分化好(G1级)者表达明显高于分化较差(G2、G3级)者。原位杂交实验检测结果显示,在所有的卵巢癌标本中NM23-H1B基因mRNA阳性表达率为100%(40/40),在正常卵巢组织中阳性表达率为0,在8份卵巢交界性肿瘤标本中,有2份NM23-H1B基因表达阳性,阳性表达率为2/8。结论NM23-H1B基因与卵巢癌发生发展有相关性。

Objective To study the expression of the human novel gene NM23-H1B in ovarian cancer. Methods Forty-eight samples from patients with ovarian tumor at different clinical stages and 8 from normal ovaries were examined for NM23-H1B mRNA expression by using RT-PCR, northern blot and in situ hybridization. Results All samples expressed NM23-H1B mRNA through RT-PCR, while the level of expression in ovarian tumor was higher than that of normal ovary. The level of expression in early stage （ stage Ⅰ and Ⅱ ） cancer was higher than in advanced （ stage Ⅲ and Ⅳ ） cancer. The results of northern blot showed that NM23-H1B was over expressed in ovarian cancer while low expressed in normal ovary or low malignant potential （LMP） ovarian cancer. In early stage carcinoma, the expression level was related with the differentiation of tumor cell. Well-differentiated cancer expressed NM23-H1B mRNA at comparatively higher level. The result of in situ hybridization showed that positive expression rate of NM23-H1B mRNA in ovarian cancer （100%, 40/40） was significantly higher than that in normal ovary （0/8） or LMP ovarian cancer （2/8）. Conclusion The novel gene NM23-H1B is related to ovarian cancer.